This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Thursday, June 2, 2016
One gene, protein suppresses Cancer tumor formation
Pten (short for phosphatase and tensin homolog) is a tumor suppressor
that is defective in about 20-25 percent of all patients with cancers.
Mayo Clinic researchers now have discovered that Pten safeguards against
tumor formation by keeping chromosome numbers intact when a cell splits
into two daughter cells. In this study, the last three amino acids of
the Pten protein, which are often missing in human cancers, were found
to be critical. Pten is the most prominent human tumor suppressor after p53. The current
thinking is that Pten's phosphatase activity counteracts PI3 kinase
activity. Loss of this function causes tumor formation through
uncontrolled stimulation of AKT, an enzyme that stimulates cell
proliferation and survival and is often hyperactive in human tumors. "We found that Pten localizes to mitotic spindle poles to recruit the
'motor' protein EG5, which moves the poles apart to form a perfectly
symmetrical bipolar spindle that accurately separates duplicated
chromosomes," says senior author Jan van Deursen, Ph.D., a molecular
biologist and cancer researcher at Mayo Clinic. The research team
further found that the recruitment process involves Dlg1, an Eg5-binding
protein that docks to the last three Pten amino acids at spindles
poles. Importantly, mutant mice lacking these amino acids have abnormal
chromosome numbers and form tumors at high frequency. The researchers
say these new findings predict that a large proportion of Pten tumors
will be hypersensitive to Eg5-inhibiting drugs, providing new
opportunities for targeted cancer therapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment